AKT1 and thyroid cancer: Altogether, the above findings indicate that DSF/Cu improves the response of BRAFV600E-mutated thyroid cancer cells to PLX4032 by relieving feedback activation of MAPK/ERK and PI3K/AKT signaling pathways.